Toxicity, biodistribution and oxidative damage caused by zirconia nanoparticles after intravenous injection
Yue Yang,Huihui Bao,Qianqian Chai,Zhiwen Wang,Zhenning Sun,Changhui Fu,Zhaoping Liu,Zhongjie Liu,Xianwei Meng,Tianlong Liu
DOI: https://doi.org/10.2147/IJN.S197565
IF: 7.033
2019-11-22
International Journal of Nanomedicine
Abstract:Yue Yang, 1,2 Huihui Bao, 1 Qianqian Chai, 3 Zhiwen Wang, 2 Zhenning Sun, 2 Changhui Fu, 3 Zhaoping Liu, 1 Zhongjie Liu, 2 Xianwei Meng, 3 Tianlong Liu 2 1 China National Center for Food Safety Risk Assessment, Beijing 100022, People's Republic of China; 2 Key Laboratory of Animal Epidemiology of Ministry of Agriculture, College of Veterinary Medicine, China Agricultural University, Beijing 100193, People's Republic of China; 3 Laboratory of Controllable Preparation and Application of Nanomaterials, Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Beijing 100190, People's Republic of China Background: As a promising nanomaterial for biomedical applications, zirconia nanoparticles (ZrO 2 ) have aroused concern recently, but the toxicity of ZrO 2 in vivo has received little attention. Purpose: The aim of this study is to demonstrate the systematic single dose toxicity, biodistribution and oxidative damage of ZrO 2 in vivo after intravenous injection in mice. Materials and methods: Ten ICR mice were used at the high dose of ZrO 2 including 600, 500, 400 and 300mg/kg. Maximum tolerated dose (MTD) of 150 nm ZrO 2 was determined as 500mg/kg. Hematology analysis and blood biochemical assay were determined for the evaluation of oxidative damage caused by ZrO 2 . Biodistribution of ZrO 2 was investigated by ICP-OES and TEM. Results: Mice treated with higher dose (500mg/kg) showed significant spread in white blood cell counts ( p <0.05). Especially, the serum ALT levels of 500mg/kg groups increased significantly ( p <0.05) compared with the control group. ZrO 2 particles would not induce any changes in appearance and micromorphology of liver at 100 and 350mg/kg. Spleen samples showed no significant changes in micromorphology of the lymphoid follicles and in the size of the red pulp after injection of ZrO 2 at all doses. The serum of ZrO 2 -treated animals (350 and 500mg/kg) has reduced levels of SOD compared to the control group ( p <0.05). ZrO 2 persists in membrane-enclosed vesicles called lysosomes in the liver and spleen macrophages without abnormal changes of ultrastructure. Conclusion: These findings would contribute to the future development of ZrO 2 -based drug delivery system and other biomedical applications. Keywords: zirconia nanoparticles, toxicity, biodistribution, oxidative damage, ICP-OES
pharmacology & pharmacy,nanoscience & nanotechnology